logo

FULC

Fulcrum Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.84 / 10
Netural

Fund flow analysis shows a good score (7.63/10) with positive Small-scale inflows (0.502) but negative Medium- and Large-scale trends. This indicates short-term money is entering, yet larger institutions are stepping back, aligning with the overall neutral price trend. Coupled with an overwhelmingly bullish analyst consensus (Strong Buy 50%, Buy 25%), the data suggest that retail or nimble funds are driving activity while bigger players remain cautious.

FundamentalSentiment(4.84)Technical
Fund Flow Rating
Analyst RatingStrong Buy

Wall Street Opinions

Strong Buy

Strong Buy

50%

Buy

25%

Hold

0%

Sell

13%

Strong Sell

0%

Date2025-12-08
InstitutionHC Wainwright & Co.
Times predicted3
Historical Win Rate33.3%
What is the analyst consensus for FULC?
  • FULC holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.84/10 (Netural).